Literature DB >> 20926145

The impact of rapid atrial pacing on ADMA and endothelial NOS.

Andreas Goette1, Matthias Hammwöhner, Alicja Bukowska, Fortunato Scalera, Jens Martens-Lobenhoffer, Dobromir Dobrev, Ursula Ravens, Soenke Weinert, Senad Medunjanin, Uwe Lendeckel, Stefanie M Bode-Böger.   

Abstract

BACKGROUND: The endothelial nitric oxide synthase (eNOS) inhibitor asymmetric dimethylarginine (ADMA) is a well-established risk factor for oxidative stress, vascular dysfunction, and congestive heart failure. The aim of the present study was to determine the impact of rapid atrial pacing (RAP) on ADMA levels and eNOS expression. METHODS AND
RESULTS: ADMA levels were studied in 60 age- and gender-matched patients. Thirty five patients had persistent atrial fibrillation (AF)≥ 4months. In AF-patients, parameters were studied before and 24h after electrical cardioversion. Moreover, ADMA, eNOS expression, and calcium-handling proteins were studied in pigs subjected to RAP as well as in endothelial cell (EC) cultures. ADMA level was significantly higher in AF compared to sinus rhythm patients (p=0.024). ADMA was highest in AF-patients, who also showed elevated troponin T (TnT) levels. Moreover, ADMA showed a significant linear correlation to TnT (r=0.47; p<0.01). After electrical cardioversion ADMA returned to normal within 24h. In pigs, RAP for 7h increased ADMA levels (p=0.018) and TnI (p<0.05), and reduced mRNA expression of ventricular and aortic eNOS (-80%; p<0.05) compared to sham-control. However, ADMA per se did not affect eNOS mRNA level in EC cultures.
CONCLUSION: The current study shows that acute and persistent episodes of atrial tachyarrhythmia are associated with elevated ADMA levels accompanied by increased ischemic myocardial markers. Moreover, RAP increases ADMA and down-regulates eNOS expression in an ADMA-independent manner. We conclude that the combination of these two separate and potentially synergistic mechanisms may contribute to long-term vascular injury during atrial tachyarrhythmia.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20926145     DOI: 10.1016/j.ijcard.2010.09.004

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  19 in total

Review 1.  EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: Definition, characterization, and clinical implication.

Authors:  Andreas Goette; Jonathan M Kalman; Luis Aguinaga; Joseph Akar; Jose Angel Cabrera; Shih Ann Chen; Sumeet S Chugh; Domenico Corradi; Andre D'Avila; Dobromir Dobrev; Guilherme Fenelon; Mario Gonzalez; Stephane N Hatem; Robert Helm; Gerhard Hindricks; Siew Yen Ho; Brian Hoit; Jose Jalife; Young-Hoon Kim; Gregory Y H Lip; Chang-Sheng Ma; Gregory M Marcus; Katherine Murray; Akihiko Nogami; Prashanthan Sanders; William Uribe; David R Van Wagoner; Stanley Nattel
Journal:  Heart Rhythm       Date:  2016-06-10       Impact factor: 6.343

2.  Platelet hyperaggregability in patients with atrial fibrillation. Evidence of a background proinflammatory milieu.

Authors:  Nathan E K Procter; Jocasta Ball; Doan T M Ngo; Yuliy Y Chirkov; Jeffrey S Isenberg; Elaine M Hylek; Simon Stewart; John D Horowitz
Journal:  Herz       Date:  2015-07-02       Impact factor: 1.443

3.  Atrial fibrillation pacing decreases intravascular shear stress in a New Zealand white rabbit model: implications in endothelial function.

Authors:  Nelson Jen; Fei Yu; Juhyun Lee; Steve Wasmund; Xiaohu Dai; Christina Chen; Pai Chawareeyawong; Yongmo Yang; Rongsong Li; Mohamed H Hamdan; Tzung K Hsiai
Journal:  Biomech Model Mechanobiol       Date:  2012-09-15

4.  Asymmetric dimethylarginine, related arginine derivatives, and incident atrial fibrillation.

Authors:  Renate B Schnabel; Renke Maas; Na Wang; Xiaoyan Yin; Martin G Larson; Daniel Levy; Patrick T Ellinor; Steven A Lubitz; David D McManus; Jared W Magnani; Dorothee Atzler; Rainer H Böger; Edzard Schwedhelm; Ramachandran S Vasan; Emelia J Benjamin
Journal:  Am Heart J       Date:  2016-03-17       Impact factor: 4.749

Review 5.  Endothelial function in patients with atrial fibrillation.

Authors:  Ahsan A Khan; Graham N Thomas; Gregory Y H Lip; Alena Shantsila
Journal:  Ann Med       Date:  2020-01-10       Impact factor: 4.709

6.  Nitric oxide synthases and atrial fibrillation.

Authors:  Ingrid M Bonilla; Arun Sridhar; Sandor Györke; Arturo J Cardounel; Cynthia A Carnes
Journal:  Front Physiol       Date:  2012-04-23       Impact factor: 4.566

7.  MicroRNA profiling of atrial fibrillation in canines: miR-206 modulates intrinsic cardiac autonomic nerve remodeling by regulating SOD1.

Authors:  Yujiao Zhang; Shaohua Zheng; Yangyang Geng; Jiao Xue; Zhongsu Wang; Xinxing Xie; Jiangrong Wang; Shuyu Zhang; Yinglong Hou
Journal:  PLoS One       Date:  2015-03-27       Impact factor: 3.240

8.  Atrial Fibrillation Is Associated with a Marker of Endothelial Function and Oxidative Stress in Patients with Acute Myocardial Infarction.

Authors:  Karim Stamboul; Julie Lorin; Luc Lorgis; Charles Guenancia; Jean-Claude Beer; Claude Touzery; Luc Rochette; Catherine Vergely; Yves Cottin; Marianne Zeller
Journal:  PLoS One       Date:  2015-07-09       Impact factor: 3.240

9.  Plasma asymmetric dimethylarginine and adverse events in patients with atrial fibrillation referred for coronary angiogram.

Authors:  Tze-Fan Chao; Tse-Min Lu; Yenn-Jiang Lin; Hsuan-Ming Tsao; Shih-Lin Chang; Li-Wei Lo; Yu-Feng Hu; Ta-Chuan Tuan; Ming-Hsiung Hsieh; Shih-Ann Chen
Journal:  PLoS One       Date:  2013-08-07       Impact factor: 3.240

Review 10.  Targeting inflammation and oxidative stress in atrial fibrillation: role of 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibition with statins.

Authors:  Ana Catarina Pinho-Gomes; Svetlana Reilly; Ralf P Brandes; Barbara Casadei
Journal:  Antioxid Redox Signal       Date:  2013-10-19       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.